跳到正文
原文
FiercePharma· @FiercePharma · X·· 2026-10-16AI 评分42
AI 导读

礼来正为炎症性肠病治疗提出更高标准。新的Omvoh分析显示,即使其他生物制剂治疗失败后,患者仍能同时实现多个治疗目标。https://www.fiercepharma.com/pharma/new-omvoh-analyses-lilly-argues-higher-bar-ibd-treatment-within-reach

正文

Eli Lilly is making the case for a higher bar in inflammatory bowel disease treatment. New Omvoh analyses show patients achieving multiple treatment goals simultaneously, even after other biologics failed. https://www.fiercepharma.com/pharma/new-omvoh-analyses-lilly-argues-higher-bar-ibd-treatment-within-reach

来源:FiercePharma · x.com